BFRG BULLFROG AI HOLDINGS

BullFrog AI Files Quarterly Report on Form 10-Q

BullFrog AI Files Quarterly Report on Form 10-Q

GAITHERSBURG, Md., May 26, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced it filed its Form 10-Q with the Securities and Exchange Commission (“SEC”) for the quarter ended March 31, 2023.

BullFrog AI received notice from Nasdaq on May 23, 2023, notifying the Company that it was not in compliance with the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) because the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2023 was not filed with the Securities and Exchange Commission by the required due date. The Company is now in compliance with Nasdaq Listing Rule 5250(c)(1).

About BullFrog AI

BullFrog AI is a digital technology company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may seek to receive the therapies they need.

For more information visit BullFrogAI at

Website:

LinkedIn:

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Contact:

Dave Gentry

RedChip Companies, Inc.



800-733-2447

SOURCE: BullFrog AI Holdings, Inc.



EN
26/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BULLFROG AI HOLDINGS

 PRESS RELEASE

BullFrog AI Publishes Whitepaper on AI in Bioinformatics: Turning Comp...

BullFrog AI Publishes Whitepaper on AI in Bioinformatics: Turning Complex Data into Actionable Insights New publication details how BullFrog Data Networks® and bfLEAP® technology address fundamental AI challenges in drug discovery and development GAITHERSBURG, Md., Nov. 18, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the publication of a new whitepaper titled “A...

 PRESS RELEASE

BullFrog AI to Present bfPREP at the AI Drug Discovery & Development S...

BullFrog AI to Present bfPREP at the AI Drug Discovery & Development Summit 2025 Technical insights session to highlight human-in-the-loop AI agent workflows in drug development GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that it will present a technical talk at the upcoming AI Drug Discovery & Development Summit 2025, taking place No...

 PRESS RELEASE

BullFrog AI Announces Abstract Accepted for Presentation at 2026 ASCO ...

BullFrog AI Announces Abstract Accepted for Presentation at 2026 ASCO Gastrointestinal Cancers Symposium AI-driven precision-oncology analysis identifies patient subtypes with potential enhanced response to glufosfamide Accepted ASCO abstract, submitted in collaboration with Eleison Pharmaceuticals, provides further validation of BullFrog AI’s technology GAITHERSBURG, Md., Nov. 04, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successf...

 PRESS RELEASE

Join BullFrog AI’s Exclusive Live Investor Webinar and Q&A Session on ...

Join BullFrog AI’s Exclusive Live Investor Webinar and Q&A Session on October 30 GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, is pleased to invite investors to a webinar on October 30, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature BullFrog AI’s founder and CEO, Vin Singh. Attendees will gain insights into BullFro...

 PRESS RELEASE

BullFrog AI Expands Sales and Marketing Team to Accelerate Commercial ...

BullFrog AI Expands Sales and Marketing Team to Accelerate Commercial Adoption of Clinical Trial Optimization Solutions and bfPREP™ Module GAITHERSBURG, Md., Sept. 30, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the expansion of its internal sales organization to support accelerated commercialization of the Company’s clinical trial optimization offerings, includin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch